Quince Therapeutics (QNCX) Institutional Ownership → I’m afraid WWIII is a very real possibility (From Porter & Company) (Ad) Free QNCX Stock Alerts $0.90 -0.01 (-1.09%) (As of 05/17/2024 ET) Add Compare Share Share OwnershipStock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media Institutional Ownership Changes (13F Filings) for Quince Therapeutics (NASDAQ:QNCX)CurrentInstitutional OwnershipPercentage30.75%Number ofInstitutional Buyers(last 12 months)3TotalInstitutional Inflows(last 12 months)$2.30MNumber ofInstitutional Sellers(last 12 months)0 Get QNCX Insider Trade Alerts Want to know when executives and insiders are buying or selling Quince Therapeutics stock? Sign up for InsiderTrades.com's daily newsletter to get the latest insider transactions delivered to your inbox daily. Email Address Skip Chart & View Institutional Buying and Selling Data QNCX Institutional Buying and Selling by Quarter Ad Crypto 101 MediaThe Overlooked Retirement Asset You Probably Don’t Own4 out of 5 Americans believe we’re on the brink of a retirement crisis. Luckily, in these unprecedented times, we have an unprecedented solution. Once considered a “fringe” investment, the crypto market is now taking the world by storm.Click here to access the Crypto Retirement Blueprint now. Quince Therapeutics Major Shareholders & Ownership History Export to ExcelReporting DateMajor Shareholder NameShares HeldMarket Value% of PortfolioQuarterly Change in SharesOwnership in CompanyDetails1/12/2024 Scharf Investments LLC91,061$96K0.0%N/A0.212% 7/31/2023 Intellectus Partners LLC53,527$81K0.0%N/A0.148% 7/24/2023 BML Capital Management LLC1,411,839$2.13M1.9%N/A3.892% 5/11/2023 EPIQ Capital Group LLC958,469$1.50M0.8%-9.3%2.642% 4/20/2023 Hennion & Walsh Asset Management Inc.31,061$48K0.0%N/A0.086% (Data available from 1/1/2016 forward) QNCX Institutional Ownership - Frequently Asked Questions Who are the largest shareholders of QNCX shares? During the previous two years, the following institutional investors and hedge funds held shares of Quince Therapeutics shares: BML Capital Management LLC ($2.13M), EPIQ Capital Group LLC ($1.50M), Scharf Investments LLC ($96K), and Intellectus Partners LLC ($81K), Hennion & Walsh Asset Management Inc. ($48K).Learn more on QNCX's institutional investors. What percentage of Quince Therapeutics stock is owned by institutional investors? 30.75% of Quince Therapeutics stock is owned by institutional investors. Learn more on QNCX's institutional investor holdings. Which institutional investors have been buying Quince Therapeutics stock? The following institutional investors have purchased Quince Therapeutics stock in the last 24 months: BML Capital Management LLC ($1.41M), Scharf Investments LLC ($91.06K), Intellectus Partners LLC ($53.53K), and Hennion & Walsh Asset Management Inc. ($31.06K). How much institutional buying is happening at Quince Therapeutics? Institutional investors have bought a total of 1,587,488 shares in the last 24 months. This purchase volume represents approximately $2.35M in transactions. Which Quince Therapeutics major shareholders have been selling company stock? The following institutional investors have sold Quince Therapeutics stock in the last 24 months: EPIQ Capital Group LLC ($97.72K). How much institutional selling is happening at Quince Therapeutics? Institutional investors have sold a total of 97,722 shares in the last 24 months. This volume of shares sold represents approximately $152.45K in transactions. Related Companies: MiNK Therapeutics Major Shareholders Estrella Immunopharma Major Shareholders Cyclo Therapeutics Major Shareholders SAB Biotherapeutics Major Shareholders Achilles Therapeutics Major Shareholders OKYO Pharma Major Shareholders Pluri Major Shareholders Dyadic International Major Shareholders Brainstorm Cell Therapeutics Major Shareholders Surrozen Major Shareholders This page (NASDAQ:QNCX) was last updated on 5/18/2024 by MarketBeat.com Staff From Our PartnersCEO of Biggest AI Chipmaker Just Dropped a Bombshell…Banyan Hill PublishingHe called Apple at $1.49 and now he says: “Buy these 6 AI stocks.”InvestorPlaceThe Overlooked Retirement Asset You Probably Don’t OwnCrypto 101 MediaWhat’s Really Next for America…Porter & Company[URGENT] DO NOT Touch These AI Stocks!Weiss RatingsA letter is coming from the "Bureau of the Fiscal Service".Stansberry ResearchClaim Your Complimentary Bitcoin RewardCrypto Swap ProfitsExposed: 10 CENT Crypto to Explode May 20th?True Market Insiders Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Quince Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
